FindTrial
Sign In

Comparative Study of Efficacy and Safety of Travoprost 0.004 percent Versus Timolol 0.5 percent Eye Drops in Primary Open-Angle Glaucoma Patients

Comparative Efficacy and Safety of Topical Eye Drops Travoprost 0.004 percent Versus Timolol 0.5 percent in Patients with Primary Open Angle Glaucoma in a Tertiary Care Teaching Hospital A Prospective Open Label Parallel Group Study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/12/078224
Enrollment
42
Registered
2024-12-17
Start date
Unknown
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H401- Open-angle glaucoma

Interventions

Intervention1: Travoprost 0.004 percent eye drops : Group A will receive Travoprost 0.004 percent 1 drop per eye once daily (9 PM evening) and assessed at baseline, 4 weeks, 8 weeks and 12 weeks Con

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients aged = 40 years of either gender 2. Best corrected visual acuity = 6 / 60 3. Newly diagnosed patients of primary open-angle glaucoma with mean intraocular pressure (IOP) of 24-36 mm Hg in at least one eye 4. Subjects willing to give written informed consent

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
difference of reduction in mean intraocular pressure in patients with Primary Open Angle Glaucoma receiving Travoprost 0.004% and Timolol 0.5 % eye drops from baseline at the end of 12 weeksTimepoint: from baseline at the end of 12 weeks—

Secondary

MeasureTime frame
1.Incidence of adverse events reported by patients with Primary Open Angle Glaucoma receiving Travoprost 0.004% and timolol 0.5 % eye drops from baseline at the end of 12 weeks 2.Assessment of medication adherence – comparison of medication adherence to study drug will be done by medication adherence reporting scale (MARS-10) Timepoint: from baseline at the end of 12 weeks—

Countries

India

Contacts

Public ContactDR RITU RUCHI KERKETTA

MUHS

chelsycosmos@rediffmail.com8208941958

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026